These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34936301)

  • 1. Targeting Neuregulin 1 (NRG1): A Novel Biomarker for Non-Small-Cell Lung Cancer.
    Fang C; Kang B; Zhao P; Ran J; Wang L; Zhao L; Luo H; Tao L
    J Environ Pathol Toxicol Oncol; 2021; 40(4):61-72. PubMed ID: 34936301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NRG1 and NRG2 fusions in non-small cell lung cancer (NSCLC): seven years between lights and shadows.
    Trombetta D; Sparaneo A; Fabrizio FP; Di Micco CM; Rossi A; Muscarella LA
    Expert Opin Ther Targets; 2021 Oct; 25(10):865-875. PubMed ID: 34706602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
    Shin DH; Jo JY; Han JY
    Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring
    Kim DW; Schram AM; Hollebecque A; Nishino K; Macarulla T; Rha SY; Duruisseaux M; Liu SV; Al Hallak MN; Umemoto K; Wesseler C; Cleary JM; Springfeld C; Neuzillet C; Joe A; Jauhari S; Ford J; Goto K
    Future Oncol; 2024; 20(16):1057-1067. PubMed ID: 38348690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
    Zhou Y; Li S; Li J; Wang D; Li Q
    Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VAMP2-NRG1 Fusion Gene is a Novel Oncogenic Driver of Non-Small-Cell Lung Adenocarcinoma.
    Jung Y; Yong S; Kim P; Lee HY; Jung Y; Keum J; Lee S; Kim J; Kim J
    J Thorac Oncol; 2015 Jul; 10(7):1107-11. PubMed ID: 26134228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Afatinib Treatment for Advanced Mixed Non-small Cell Lung Cancer 
with CRISPLD2-NRG1 Fusion: A Case Report and Literature Review].
    Chen C; Yu Y; Huang M
    Zhongguo Fei Ai Za Zhi; 2024 May; 27(5):399-404. PubMed ID: 38880928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report.
    Nie X; Zhang P; Bie Z; Song C; Zhang M; Ma D; Cui D; Cheng G; Li H; Lei Y; Su X; Wu W; Li L
    World J Surg Oncol; 2023 Aug; 21(1):246. PubMed ID: 37587479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway.
    Liu L; Zhou XY; Zhang JQ; Wang GG; He J; Chen YY; Huang C; Li L; Li SQ
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8722-8730. PubMed ID: 30575912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.
    Schram AM; Odintsov I; Espinosa-Cotton M; Khodos I; Sisso WJ; Mattar MS; Lui AJW; Vojnic M; Shameem SH; Chauhan T; Torrisi J; Ford J; O'Connor MN; Geuijen CAW; Schackmann RCJ; Lammerts van Bueren JJ; Wasserman E; de Stanchina E; O'Reilly EM; Ladanyi M; Drilon A; Somwar R
    Cancer Discov; 2022 May; 12(5):1233-1247. PubMed ID: 35135829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
    Sequist LV; Gray JE; Harb WA; Lopez-Chavez A; Doebele RC; Modiano MR; Jackman DM; Baggstrom MQ; Atmaca A; Felip E; Provencio M; Cobo M; Adiwijaya B; Kuesters G; Kamoun WS; Andreas K; Pipas JM; Santillana S; Cho BC; Park K; Shepherd FA
    Oncologist; 2019 Aug; 24(8):1095-1102. PubMed ID: 30975923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low expression of Mig-6 is associated with poor survival outcome in NSCLC and inhibits cell apoptosis via ERK-mediated upregulation of Bcl-2.
    Li Z; Qu L; Zhong H; Xu K; Qiu X; Wang E
    Oncol Rep; 2014 Apr; 31(4):1707-14. PubMed ID: 24573418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.
    Mendell J; Freeman DJ; Feng W; Hettmann T; Schneider M; Blum S; Ruhe J; Bange J; Nakamaru K; Chen S; Tsuchihashi Z; von Pawel J; Copigneaux C; Beckman RA
    EBioMedicine; 2015 Mar; 2(3):264-71. PubMed ID: 26137564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of Rab17 promotes cell proliferation and invasion in non-small cell lung cancer through STAT3/HIF-1α/VEGF signaling.
    Wang M; Wang W; Ding J; Wang J; Zhang J
    Thorac Cancer; 2020 Feb; 11(2):379-388. PubMed ID: 31841274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum miR-185 Is a Diagnostic and Prognostic Biomarker for Non-Small Cell Lung Cancer.
    Liu J; Han Y; Liu X; Wei S
    Technol Cancer Res Treat; 2020; 19():1533033820973276. PubMed ID: 33251978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
    Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W
    Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155
    [No Abstract]   [Full Text] [Related]  

  • 18. LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p/YAP1 axis.
    He W; Zhang Y; Xia S
    Thorac Cancer; 2020 Mar; 11(3):549-560. PubMed ID: 31923353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
    Lu C; Shan Z; Hong J; Yang L
    Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of NRG1 Gene Fusions in a Large Population of Chinese Patients with NSCLC.
    Ke H; Shen W; Hu A; Ou Q; Lu S
    J Thorac Oncol; 2019 Dec; 14(12):e263-e266. PubMed ID: 31757375
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.